This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test
by Zacks Equity Research
Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe
by Zacks Equity Research
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
by Zacks Equity Research
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
What's in Store for West Pharmaceutical's (WST) Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.
Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.
Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.
Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.
AMN Healthcare Services (AMN) Stock Moves -1.46%: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $103.75 in the latest trading session, marking a -1.46% move from the prior day.
AMN Healthcare Services (AMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AMN Healthcare (AMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.
Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Baxter's (BAX) strong product portfolio.